Impact of COINS Act Expansion on China Biotech Licensing

Key Takeaways

• H.R. 9102, the Biotech Investment National Security Act of 2026, was introduced June 2, 2026.
• Sponsors are Rep. John Moolenaar and Rep. Debbie Dingell; the bill was referred to House Financial Services.
• Draft text prioritizes screening of IP licensing, drug-discovery platforms, clinical R&D, and biologics manufacturing know-how.
• Agricultural biotech, industrial fermentation unrelated to therapeutics, and basic academic research are carved out in the draft.

What does BINSA propose to change in COINS screening?

H.R. 9102 would amend title VIII of the Defense Production Act definitions of “prohibited technology” and “notifiable technology” to pull biotechnology into the outbound investment security framework associated with the COINS Act.

In plain terms for BD teams: equity wires are not the only risk. Licensing and IP transfer sit at the center of the draft.

The short title in the introduced text is the Biotech Investment National Security Act of 2026, or the BINSA Act.

Which China-facing deal types would face review?

Introduced text instructs Treasury, within one year of enactment, to issue a rule further defining “biotechnology” parameters.

When doing so, Treasury must consult HHS, Defense, and the Director of National Intelligence.

Particular consideration is directed to licensing transactions, joint ventures, and equity investments involving drug discovery platforms, clinical development capabilities, and biologics manufacturing—plus related intellectual property and know-how transfers.

What is explicitly excluded?

The draft tells Treasury not to define the biotechnology sector in a way that includes agricultural biotechnology, industrial fermentation unrelated to pharmaceutical or therapeutic production, or basic academic research with no direct pharmaceutical application.

That carve-out matters for platforms that mix ag/industrial biology with human therapeutics—deal counsel will need a use-case map.

Until a final rule exists, treat the exclusions as legislative intent, not operative safe harbors.

What reporting would Defense owe Congress?

Within 60 days of enactment, the Secretary of Defense would submit a report assessing whether U.S. capital flows into China’s biotechnology sector—including licensing with Chinese biotech firms—negatively affect national security and military readiness.

That report is a political catalyst as much as an analytical product. Expect it to be cited in hearings even if BINSA stalls.

Primary bill text is available via Congress.gov introduced text and GovInfo mirrors when published.

What should licensing and BD teams do before enactment?

Inventory active and pipeline China inbound licenses, options, and co-dev structures that transfer know-how, not just finished-product distribution rights.

Add “outbound screening contingency” language to term sheets: closing conditions, reverse break fees, and alternative manufacturing footprints if Treasury review appears.

Do not assume BIOSECURE procurement limits are the same legal regime; BINSA targets private capital and IP flows under the outbound program.

How does this connect to other China–pharma coverage?

Benchmark against NovaPharmaNews files on China as an R&D partner, China capital-efficiency dynamics, and cross-border licensing structures.

Those articles describe commercial gravity. BINSA describes a potential legal filter on that gravity.

Until Congress acts, model both “status quo COINS sectors” and “biotech added” cases in board risk memos.

Keep Congress.gov bill text linked in every China licensing diligence binder.

If enacted, Treasury’s one-year rulemaking clock becomes the critical path for deal timing.

Watch House Financial Services markup calendars for amendments that widen or narrow licensing coverage.

Exclusions for ag biotech and basic research will draw lobbying. Do not rely on them yet.

Board memos should show a BINSA-pass case and a BINSA-fail case for large China options.

Banks and corporate VC arms need the same screen even when the pharma partner sits offshore.

Counsel should flag know-how annexes that teach cell-line methods, not only finished-drug distribution.

Update board risk matrices with a qualitative ‘China outbound screen’ line even before final text exists.

Until referral turns into markup, treat the bill as signaling risk that can still move counterparties.

BINSA is bipartisan in sponsorship, which raises odds of attachment to a larger vehicle even if stand-alone passage is hard.

Companies mid-negotiation on China-origin ADCs or oral GLP-1 assets need alternate supply clauses now.

Defense reporting within 60 days of enactment would create a fast political feedback loop.

Treasury consultation with HHS implies clinical and public-health equities will enter national-security review.

Structure diligence questionnaires to ask who receives cell banks, assay methods, and batch records.

Cross-border option deals that look like research collaborations can still transfer manufacturing know-how.

Frequently Asked Questions

Primary Sources

• Congress.gov — H.R. 9102 (BINSA Act)
• Congress.gov — H.R. 9102 introduced text
• GovInfo — U.S. government publication system